Comparative Pharmacology
Head-to-head clinical analysis: AMMONIA N 13 versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIA N 13 versus NEPHROSCAN.
AMMONIA N 13 vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical